Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA.
Department of Medicine, University of Chicago, Chicago, USA.
Neoplasia. 2020 Aug;22(8):283-293. doi: 10.1016/j.neo.2020.05.002. Epub 2020 May 16.
Squamous cell carcinoma of the head and neck (SCCHN) is a malignancy with poor outcomes, thus novel therapies are urgently needed. We recently showed that WHSC1 is necessary for the viability of SCCHN cells through H3K36 di-methylation. Here, we report the identification of its novel substrate, histone H1, and that WHSC1-mediated H1.4K85 mono-methylation may enhance stemness features in SCCHN cells. To identify proteins interacting with WHSC1 in SCCHN cells, WHSC1 immunoprecipitation and mass spectrometry identified H1 as a WHSC1-interacting candidate. In vitro methyltransferase assays showed that WHSC1 mono-methylates H1 at K85. We generated an H1K85 mono-methylation-specific antibody and confirmed that this methylation occurs in vivo. Sphere formation assays using SCC-35 cells stably expressing either wild-type (FLAG-H1.4-WT) or mutated (FLAG-H1.4K85A) vector with lysine 85 to alanine substitution which is not methylated, indicated a higher number of spheres in SCC-35 cells expressing the wild type than those with the mutant vector. SCC-35 cells expressing the wild type H1.4 proliferated faster than those expressing the mutated vector. RNA sequencing, RT-PCR and Western blotting of the FLAG-H1.4-WT or FLAG-H1.4K85A SCC-35 cells revealed that OCT4 levels were higher in wild type compared to mutant cells. These results were reproduced in SCC-35 cells genetically modified with CRISPR to express H1.4K85R. Chromatin immunoprecipitation showed that FLAG-H1.4K85A had decreased occupancy in the OCT4 gene compared to FLAG-H1.4-WT. This study supports that WHSC1 mono-methylates H1.4 at K85, it induces transcriptional activation of OCT4 and stemness features in SCCHN cells, providing rationale to target H1.4K85 mono-methylation through WHSC1 in SCCHN.
头颈部鳞状细胞癌(SCCHN)是一种预后不良的恶性肿瘤,因此急需新的治疗方法。我们最近发现,WHSC1 通过 H3K36 二甲基化对 SCCHN 细胞的活力是必需的。在这里,我们报告了其新的底物组蛋白 H1 的鉴定,以及 WHSC1 介导的 H1.4K85 单甲基化可能增强 SCCHN 细胞的干性特征。为了鉴定与 SCCHN 细胞中 WHSC1 相互作用的蛋白质,WHSC1 免疫沉淀和质谱鉴定 H1 为 WHSC1 相互作用的候选物。体外甲基转移酶测定表明,WHSC1 在 K85 处单甲基化 H1。我们生成了一种 H1K85 单甲基化特异性抗体,并证实该甲基化在体内发生。使用 SCC-35 细胞稳定表达野生型(FLAG-H1.4-WT)或突变型(FLAG-H1.4K85A)载体的球体形成测定,其中赖氨酸 85 突变为不被甲基化的丙氨酸,表明表达野生型的 SCC-35 细胞中的球体数量多于表达突变型载体的细胞。表达野生型 H1.4 的 SCC-35 细胞比表达突变型载体的细胞增殖更快。FLAG-H1.4-WT 或 FLAG-H1.4K85A SCC-35 细胞的 RNA 测序、RT-PCR 和 Western blot 显示,与突变细胞相比,野生型细胞中的 OCT4 水平更高。在通过 CRISPR 基因修饰表达 H1.4K85R 的 SCC-35 细胞中重现了这些结果。染色质免疫沉淀显示,与 FLAG-H1.4-WT 相比,FLAG-H1.4K85A 在 OCT4 基因中的占有率降低。这项研究支持 WHSC1 在 K85 处单甲基化 H1.4,它诱导 SCCHN 细胞中 OCT4 的转录激活和干性特征,为通过 WHSC1 靶向 SCCHN 中的 H1.4K85 单甲基化提供了依据。